United Therapeutics | UTHR - Net Income

Stock Price
568.58
Daily Change
-7.21 -1.25%
Monthly
-2.06%
Yearly
86.21%
Q2 Forecast
553.25

United Therapeutics reported $274.9M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Amarin USD -1.22M 6.51M Dec/2025
Ardelyx USD -407K 562K Dec/2025
Baxter International USD -15M 1.11B Mar/2026
Bayer EUR 2.76B 6.52B Mar/2026
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
Biogen USD 319.5M 368.4M Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Emergent BioSolutions USD -261.3M 78.3M Jun/2023
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
Gilead Sciences USD 2.02B 162M Mar/2026
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
Halozyme Therapeutics USD 150.05M 291.64M Mar/2026
Insmed USD -163.56M 164.92M Mar/2026
Ionis Pharmaceuticals USD -93M 136M Mar/2026
J&J USD 5.24B 119M Mar/2026
Lexicon Pharmaceuticals USD -15.53M 2.76M Dec/2025
Moderna USD -1.34B 517M Mar/2026
Omeros USD -32.23M 23.81M Sep/2024
Pfizer USD 2.69B 4.34B Mar/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Teva Pharmaceutical Industries USD 369M 111M Mar/2026
United Therapeutics USD 274.9M 89.4M Mar/2026
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026